Pfizer Heritage

BROUGHT TO YOU BY PFIZER: A GLOBAL LEADER IN ONCOLOGY THERAPY AND BIOSIMILAR DEVOLPMENT6-11

capture

Pfizer develops innovative oncology therapies that aim to change patients’ lives

  • Pfizer currently has a number of approved oncology medicines and potential approvals in clinical development6
  • Pfizer also has numerous sterile injectable chemotherapies
  • Commited to the future, with a robust pipeline of novel cancer medicines that include biologics, small molecules, immunotherapies, and biosimilars6,11,12

Pfizer is a leading provider of oncology biosimilars

  • Pfizer currently has a broad oncology biosimilar portfolio in the market1,6-10,12,13
  • Over 10 years of global experience with oncology biosimilars11

A global leader in the devlopment and production of biologic medicines

  • Over 30 years of experience providing high-quality biologic medicines- now to over 175 countries13,14
  • Delivering medicines to patients through technologically advanced production and tracking of supply15

REFERENCES

1. RUXIENCE® Summary of Product Characteristics.
2. Data on file. Rituximab clinical overview. Pfizer Inc.
3. Yin D, Becker J-C, Melia LA. A Phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in subjects with active rheumatoid arthritis with active disease in TNF failures (REFLECTIONS B328-01). Poster FRI0309 presented at: European League Against Rheumatism (EULAR) 2014 Annual Congress; June 11-14, 2014; Paris, France. 
4. Ryan AM, Sokolowski SA, Ng C-K, et al. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®). Toxicol Pathol. 2014;42(7):1069-1081. 
5. Karnik S, Thompson MS, DeGruttola H, et al. Characterization and comparison of PF-05280586, a proposed rituximab biosimilar, to the licensed product. Poster M1038 presented at: American Association of Pharmaceutical Scientists-National Biotech Conference; May 20-22, 2013; San Diego, CA. 
6. Data on file. Pfizer oncology strategy and pipeline. Pfizer Inc.
7. RETACRIT® Summary of Product Characteristics.
8. TRAZIMERA® Summary of Product Characteristics. 
9. NIVESTIM® Summary of Product Characteristics.
10. ZIRABEV® Summary of Product Characteristics.
11. Data on file. Oncology at Pfizer narrative. Pfizer Inc. New York, NY. 2018. 
12. Pfizer Inc. Product pipeline. https://www.pfizer.com/science/drug-product-pipeline. Last Accessed: January 2021. 
13. Data on file. Certification of biosimilar claims. Pfizer Inc. New York, NY. 2016. 
14. Data on file. Pfizer global supply: overview. Pfizer Inc, New York, NY. 2018. 
15. Pfizer breaks ground on new biologics clinical manufacturing facility in Andover, Massachusetts [press release]. New York, NY: Pfizer Inc.; June 16, 2016. 

 

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SPC for how to report adverse reactions.

Legal Category: POM S1A

PP-RIT-IRL-0038. Preparation Date: April 2022